Document:

Neptune Technologies & Bioressources Inc.: Exhibit 4.10 - Filed by newsfilecorp.com

Exhibit 4.10

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

MATERIAL CHANGE REPORT 

	Pursuant to: 	Part 7 of National Instrument 51-102. 
	  	  
	Item 1. 	Reporting Issuer: 
	 	 
	  	Neptune Technologies & Bioressources Inc.
    
	  	225 Promenade du Centropolis, Suite 200 
	  	Laval (QC) H7T 0B3 
	  	  
	Item 2. 	Date of Material Change: 
	  	  
	  	March 31, 2011 
	  	  
	Item 3. 	Press release: 
	  	  
		News releases announcing the material change
      referred to in this report were issued through CNW on March 30, 2011 and
      March 31, 2011. 
	  	  
	Item 4. 	Summary of Material Change: 
	 	 
		The Listing of Acasti Pharma Inc. Class A
      Common Shares on the TSX Venture Exchange. 
	  	  
	Item 5. 	Full Description of Material Change:
  
	 	 
		Acasti Pharma (“Acasti”) (TSX-V.APO), a Neptune
      Technologies & Bioressources Inc. (“Neptune”) subsidiary, announces
      that its shares will start trading today under APO ticker on the
      TSX-Venture Exchange (the “TSX-V” or “Exchange”). 
	  	  
		Acasti complied with all conditions and
      regulatory requirements of the Exchange after successfully completing the
      due diligence process led by Versant Partners, Acasti’s sponsor. No
      proceeds are raised concomitantly with the listing. A copy of Acasti’s
      listing application is available for review on SEDAR at 
    www.sedar.com. 
	  	  
	  	Pursuant to TSX-V Tier 2 issuer initial listing
      conditions and requirements: 
	  	  
		     Acasti Class B and
      Class C shares holders have converted their shares, respectively 5,000,000
      and 260,000, into Class A shares on a 1:1 basis. Following this conversion
      a total of 64,434,444 Class A shares are issued and outstanding. 
	  	  
		     Acasti modified its
      Stock Option Plan in order to comply with the exchange policy, such
      modifications to be approved by Acasti’s shareholders on their next annual
      and special meeting. 
	  	  
		     Acasti has filed
      amended financial statements for the three and nine-month periods ended
      November 30, 2010 to reflect its auditors review and the above changes
      among others in the subsequent events notes to the financial statements.
    
	  	  
		     Dr. Martin Godbout and
      Mr. Marc Lebel have been nominated as new members of the Acasti Board of
      Directors (the “Board”) following Mr. Jean-Claude Debard and Mr. Daniel
      Perry resignations on March 21, 2011 effective at the date of the listing.
      Dr. Martin Godbout is the Chairman of the Board of Director of MethylGene,
      a public company listed on the TSX Exchange, and has been involved with
      numerous biotech companies and biotech investment firms. Mr. Marc Lebel,
      Pharm.D. is the founder and former president of Anapharm, a contract
      clinical research company which he has sold to PharmaNet, he also acted as
      an Executive Vice-President of Pharmanet. Mr. Lebel sits on numerous
      private companies’ Board of Directors and currently is the President of
      Glaciel Production. Both Dr. Godbout and Mr. Lebel are elite members of
      the Excelcia Cercle and will bring a wealth of expertise to Acasti. 
	  	  
		Mr. Andre Godin has been replaced by Mr. Xavier
      Harland as the Chief Financial Officer of Acasti. Mr. Xavier Harland has
      been working as the Director of Finance for Neptune since 2004 and led the
      listing of Acasti shares on the TSX-V. Mr. Xavier Harland is an actuary, a
      Chartered Financial Analyst (“CFA”) charterholder and Financial Risk
      Manager (“FRM”) holder. 
	  	 
		Copies of the press releases issued on March
      30, 2011 and March 31, 2011 are enclosed to this report and form an
      integral part of it. 

	Item 6. 	Reliance on: Sections 7.1(2) and (3) of
      National Instrument 51-102 
	 	 
	  	Not Applicable 
	  	  
	Item 7. 	Omitted Information: 
	 	 
	  	No information has been omitted in respect of
      the material change. 
	 	 
	Item 8. 	Senior Officers: 
	 	 
		Further information with respect to the
      material change described in this material change report may be obtained
      from: 

	 	Neptune Technologies & Bioressources Inc. 
	 	André Godin 
	 	V.P. Administration and Finance 
	 	(450) 687-2262 

	Item 9. 	DATED at Montreal, Quebec, this 4th day
      of April, 2011. 

 

	 	 
	 	PRESS RELEASE 

SOURCE: Neptune
Technologies & Bioressources Inc and Acasti Pharma Inc. 

Neptune Technologies & Bioressources Inc.
Subsidiary Acasti Pharma 
Inc. Shares to Trade on
the TSX X-Venture on March 31st
Acasti
Management to Host a Teleconference 

Laval, Québec, CANADA – March 30th,
2011 – Neptune Technologies & Bioressources Inc. (“Neptune”)
(NASDAQ.NEPT - TSX.V.NTB) and Acasti Pharma Inc. (“Acasti”) (TSX.V.APO) announce
that on March 31st, 2011 Acasti shares will start trading under APO
ticker on the TSX-Venture Exchange. 

Acasti President, Tina Sampalis, and management team will host
a conference call on March 31st, 2011 at 9:00AM Eastern Daylight Time
(“EDT”), to discuss recent changes to the company’s Board of Directors and
management, as well as to provide an update on Acasti operations.

	Teleconference details are as follows:
    	  
	Time: 	9:00AM (EDT) 
	Date: 	March 31st, 2011
      
	  	  
	Participant Dial-In Number(s): 	  
	Operator Assisted Toll-Free Dial-In Number:
    	( 888 ) 241 - 0394 
	International Dial-In #: 	( 647 ) 427 - 3413 
	  	  
	Conference ID # 	56354897 

Should a participant want to submit a question to management
during Questions and Answers (“Q&A”) session, please request voice access by
sending an email to x.harland@acastipharma.com prior to the conference call. Please refer to Acasti Q&A session
access.

The recording of the teleconference will be available after the
teleconference on Neptune and Acasti websites.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation,
production and formulatio on of science-based and clinically proven novel
phospholipid products for the nutraceutical and pharmaceutical markets. The
Company focuses on growing consumer health markets including cardiovascular,
inflammatory and neurological diseases driven by consumers taking a more
proactive approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health benefits and to
obtain regulatory approval for label health claims. Neptune is continuously
expanding its intellectual property portfolio as well as clinical studies and
regulatory approvals. Neptune’s products are marketed and distributed in over 20
countries worldwide. 

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major component of
cell membranes and are essential for all vital cell processes. They are one of
the principal constituents of High Density Lipoprotein (good cholesterol) and,
as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s
proprietary novel phospholipids carry and functionalize the polyunsaturated
omega-3 fatty acids EPA and DHA, which have been shown to have substantial
health benefits and which are stabilized by potent antioxidants. Acasti Pharma
is focusing initially on treatments for chronic cardiovascular conditions within
the over-the-counter, medical food and prescription drug markets. 

1 of 2 

About NeuroBioPharm
Inc.

NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with a
multinational partner is already initiated. The development of a prescription
drug candidate is currently in progress. Advanced clinical development and
commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release."

	Neptune Contact: 	Acasti Contact: 
	Neptune Technologies & Bioressources Inc. 	Acasti Pharma Inc. 
	André Godin, V.P. Administration and Finance 	Tina Sampalis, President 
	+1.450.687.2262 	+1.450.686.4555 
	a.godin@neptunebiotech.com 	t.sampalis@acastipharma.com 
	www.neptunebiotech.com
	www.acastipharma.com 
	  	  
	CEOcast Contact: 	Howard Group Contact: 
	Dan Schustack 	Bob Beaty 
	+1 212-732-4300 	(888) 221-0915 
	dschustack@ceocast.com
	bob@howardgroupinc.com 
	www.ceocast.com 	www.howardgroupinc.com 

# # #

Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
Canadian securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from historical results
or from any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements labeled with the terms
"believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to
be uncertain and forward-looking. The forward-looking statements contained
herein are also subject generally to other risks and uncertainties that are
described from time to time in the Company's reports filed with the Securities
and Exchange Commission and the Canadian securities commissions. 

2 of 2 

 

	
     
	           
                         
                         
                         
                         
                         
                         
                         
                         
                         
                         
                   PRESS RELEASE

	SOURCE: Acasti Pharma Inc.
  

Acasti Pharma Shares to be Traded
on TSX-Venture Under APO Ticker 

Laval, Québec, CANADA – March 31, 2011 – Acasti Pharma
(“Acasti”) (TSX-V.APO), a Neptune Technologies & Bioressources Inc.
(“Neptune”) subsidiary, announces that its shares will start trading today under
APO ticker on the TSX-Venture Exchange (the “TSX-V” or “Exchange”). 

Acasti complied with all conditions and regulatory requirements
of the Exchange after successfully completing the due diligence process led by
Versant Partners, Acasti’s sponsor. No proceeds are raised concomitantly with
the listing. A copy of Acasti’s listing application is available for review on
SEDAR at www.sedar.com. 

Pursuant to TSX-V Tier 2 issuer initial listing conditions and
requirements: 

	Acasti Class B and Class C shares holders have converted their shares,
  respectively 5,000,000 and 260,000, into Class A shares on a 1:1 basis.
  Following this conversion a total of 64,434,444 Class A shares are issued and
  outstanding.
  
	Acasti modified its Stock Option Plan in order to comply with the exchange
  policy, such modifications to be approved by Acasti’s shareholders on their
  next annual and special meeting.
  
	Acasti has filed amended financial statements for the three and nine-month
  periods ended November 30, 2010 to reflect its auditors review and the above
  changes among others in the subsequent events notes to the financial
  statements.
  
	Dr. Martin Godbout and Mr. Marc Lebel have been nominated as new members
  of the Acasti Board of Directors (the “Board”) following Mr. Jean-Claude
  Debard and Mr. Daniel Perry resignations on March 21, 2011 effective at the
  date of the listing. Dr. Martin Godbout is the Chairman of the Board of
  Director of MethylGene, a public company listed on the TSX Exchange, and has
  been involved with numerous biotech companies and biotech investment firms.
  Mr. Marc Lebel, Pharm.D. is the founder and former president of Anapharm, a
  contract clinical research company which he has sold to PharmaNet, he also
  acted as an Executive Vice-President of Pharmanet. Mr. Lebel sits on numerous
  private companies’ Board of Directors and currently is the President of
  Glaciel Production. Both Dr. Godbout and Mr. Lebel are elite members of the
  Excelcia Cercle and will bring a wealth of expertise to Acasti. 

Mr. Andre Godin has been replaced by Mr. Xavier Harland as the
Chief Financial Officer of Acasti. Mr. Xavier Harland has been working as the
Director of Finance for Neptune since 2004 and led the listing of Acasti shares
on the TSX-V. Mr. Xavier Harland is an actuary, a Chartered Financial Analyst
(“CFA”) charterholder and Financial Risk Manager (“FRM”) holder. 

Rights Offering 

Upon listing of Acasti’s class A shares on the Exchange, Acasti
will offer its shareholders rights to subscribe up to an additional 15% of its
outstanding shares at a minimal price of $0.60 per share, and not less than the
Discounted Market Price permitted by the Exchange, representing a potential
aggregate financing of $5,799,100 (the “Right Offering”), immediately following
the Exchange and Autorité des Marchés Financiers (“AMF”) approvals, not yet
obtained. Acasti will be filing a request for exemption of prospectus with the
AMF with regards to the Rights Offering. Assuming all rights being exercised,
Neptune will remain a majority shareholder of Acasti, even though Neptune at the
time of the Right Offering will flowthrough directly to its shareholders the
rights it will be entitled to receive, due to its ownership in Acasti, subject
to the Exchange and AMF approvals. 

Business Update 

Acasti has begun marketing OnemiaTM to doctors and
healthcare professionals in the United States. OnemiaTM’s soft launch
has begun and has been well received by medical professionals. Acasti already
finalized its first distribution agreement and obtained its first orders for
OnemiaTM. In parallel, Acasti is finalizing negotiation to partner
with a telmed organization for the full launch of Onemia in the United States.
Acasti is also in advanced discussions and negotiation with potential
pharmaceutical partners for its VectosTM platform to be used in
combination with existing over-the-counter (“OTC”) products.

Moreover, Acasti has received comments by Health Canada
regarding the filing of its clinical trial application (“CTA”) for which the
first of two parts has been completed (Quality CMC section). Acasti expects to
obtain a letter of non–objection for its CTA from Health Canada and initiate the
clinical trial shortly. In accordance with the filing of its CTA, Acasti has
entered, on March 24, 2011, into an agreement with JSS Medical Research (“JSS”)
a clinical research organisation (“CRO”) in order to conduct, upon CTA approval
by Health Canada, the phase II clinical trial. Acasti’s Board has approved the
management recommendation for the choice of the CRO, following a rigorous due
diligence process, based on recommendations from independent third parties, as
well as on JSS experience in the field and excellent reputation, and after
revision and analysis of concurrent alternative quotes, which were all higher
than the JSS proposal. Acasti Board members, aware that JSS is owned and managed
by Dr. John Sampalis, brother of Dr. Tina Sampalis, president of Acasti,
decided, in addition to request full public disclosure, to require that
additional control and validation measures be undertaken to eliminate any doubt
and/or potential wrong perception such as appointing SNC Lavalin Pharma, an
internationally renowned organization, as external independent auditors, to
supervise the clinical trial, its achievements, milestones and payments. 

About Acasti Pharma
Inc.

Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major component of
cell membranes and are essential for all vital cell processes. They are one of
the principal constituents of High Density Lipoprotein (good cholesterol) and,
as such, play an important role in modulating cholesterol efflux. Acasti
Pharma’s proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have
substantial health benefits and which are stabilized by potent antioxidants.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular
conditions within the over-the-counter, medical food and prescription drug
markets. 

About Neptune Technologies &
Bioressources Inc.

Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven novel
phospholipid products for the nutraceutical and pharmaceutical markets. The
Company focuses on growing consumer health markets including cardiovascular,
inflammatory and neurological diseases driven by consumers taking a more
proactive approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health benefits and to
obtain regulatory approval for label health claims. Neptune is continuously
expanding its intellectual property portfolio as well as clinical studies and
regulatory approvals. Neptune’s products are marketed and distributed in over 20
countries worldwide. 

About NeuroBioPharm
Inc.

NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with a
multinational partner is already initiated. The development of a prescription
drug candidate is currently in progress. Advanced clinical development and
commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release."

	Acasti Contact: 	  
	Tina Sampalis 	Xavier Harland 
	President 	Chief Financial Officer

	+1 450.686.4555 	+1.450.687.2262 
	t.sampalis@acastipharma.com 	x.harland@acastipharma.com 
	www.acastipharma.com 	www.acastipharma.com 
	  	  
	Howard Group Contact: 	  
	Bob Beaty 	  
	(888) 221-0915 	  
	bob@howardgroupinc.com
	  
	www.howardgroupinc.com
	  

# # #

Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
Canadian securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from historical results
or from any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements labeled with the terms
"believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to
be uncertain and forward-looking. The forward-looking statements contained
herein are also subject generally to other risks and uncertainties that are
described from time to time in the Company's reports filed with the Securities
and Exchange Commission and the Canadian securities commissions. 

3 of 3Neptune Technologies & Bioressources Inc.: Exhibit 4.11 - Filed by newsfilecorp.com

Exhibit 4.11

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. 

MATERIAL CHANGE REPORT 

	Pursuant to: 	Part 7 of National Instrument 51-102. 
	 	 
	Item 1. 	Reporting Issuer: 
	 	 
	  	Neptune Technologies & Bioressources Inc.
    
	  	225 Promenade du Centropolis, Suite 200 
	  	Laval (QC) H7T 0B3 
	 	 
	Item 2. 	Date of Material Change: 
	 	 
	  	September 16, 2011 
	 	 
	Item 3. 	Press release: 
	 	 
		News release announcing the material change
      referred to in this report was issued through CNW on September 19, 2011.
    
	 	 
	Item 4. 	Summary of Material Change: 
	 	 
		The material change report of Neptune dated
      September 22, 2011, relating to Neptune entering into a Memorandum of
      Understanding (the “MOU”) with Shanghai KaiChuang Deep Sea
      Fisheries Co., Ltd. (“SKFC”) for the manufacturing and
      commercialization of Neptune’s krill products in Asia; 
	 	 
	Item 5. 	Full Description of Material Change:
  
	 	 
		Neptune entered into a MOU with SKFC to form a
      50/50 joint venture, Neptune-SKFC Biotechnology, that will manufacture and
      commercialize Neptune’s krill products in Asia. The initial cost of the
      project is expected to reach up to US$30 million (to be financed by
      Chinese banks and the parties to the joint venture) and includes the
      construction of a state-of-the-art production facility in China using
      Neptune Proprietory Technology, to develop a commercial distribution
      network for Asia. According to the MOU, Neptune will licence the right to
      its Proprietary Technology to Neptune-SKFC Biotechnology in return for an
      up-front payment and subsequent royalty payments. The MOU is subject to
      the approval by the board of each party as well as by Chinese regulators.
    
	  	  
	  	  
	Item 6. 	Reliance on: Sections 7.1(2) and (3) of
      National Instrument 51-102 
	 	 
	  	Not Applicable 
	  	  
	Item 7. 	Omitted Information: 
	 	 
	  	No information has been omitted in respect of
      the material change. 
	 	 
	Item 8. 	Senior Officers: 
	 	 
		Further information with respect to the
      material change described in this material change report may be obtained
      from: 

	 	Neptune Technologies & Bioressources Inc. 
	 	André Godin 
	 	V.P. Administration and Finance 
	 	(450) 687-2262 

	Item 9. 	DATED at Laval, Quebec, this 22nd day of
      September, 2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]